ライフサイエンスコーパス: systemic lupus erythematosus

1 by centre and patient type (with vs without systemic lupus erythematosus).

2 tica and/or giant cell arteritis to 2.82 for systemic lupus erythematosus).

3 a target of autoantibodies in patients with systemic lupus erythematosus.

4 ted in diseases, including Crohn disease and systemic lupus erythematosus.

5 ft-versus-host disease, type 1 diabetes, and systemic lupus erythematosus.

6 to three non-coding regions associated with systemic lupus erythematosus.

7 of sphingosine kinase 2 in a murine model of systemic lupus erythematosus.

8 ps, and disease severity in a mouse model of systemic lupus erythematosus.

9 l synapse that may limit immune responses in systemic lupus erythematosus.

10 oducing cells in autoimmune diseases such as systemic lupus erythematosus.

11 ultiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.

12 otide polymorphisms that are associated with systemic lupus erythematosus.

13 egy for autoantibody-driven diseases such as systemic lupus erythematosus.

14 hat it may be a viable therapeutic target in systemic lupus erythematosus.

15 erosclerosis, inflammatory bowel disease and systemic lupus erythematosus.

16 nce to the use of BAFF-targeted therapies in systemic lupus erythematosus.

17 ies was found in AA, autoimmune uveitis, and systemic lupus erythematosus.

18 oth healthy individuals and in patients with systemic lupus erythematosus.

19 nity in a classic mouse model of spontaneous systemic lupus erythematosus.

20 ing plasmablasts/PCs in patients with active systemic lupus erythematosus.

21 ctivation of intracellular innate sensors in systemic lupus erythematosus.

22 body-associated disease in a murine model of systemic lupus erythematosus.

23 haracteristic of autoimmune diseases such as systemic lupus erythematosus.

24 pressed in CD4(+) T cells from patients with systemic lupus erythematosus.

25 er of childhood and are also associated with systemic lupus erythematosus.

26 w-density granulocytes from individuals with systemic lupus erythematosus.

27 also been implicated in the pathogenesis of systemic lupus erythematosus.

28 d arthritis, inflammatory bowel disease, and systemic lupus erythematosus.

29 i-Goutieres syndrome and are associated with systemic lupus erythematosus.

30 n patients with autoimmune diseases, such as systemic lupus erythematosus.

31 trum of human autoimmune diseases resembling systemic lupus erythematosus.

32 s that lead to what is clinically defined as systemic lupus erythematosus.

33 ontributions such as Alzheimer's disease and Systemic Lupus Erythematosus.

34 ion, retinal vasculitis or inflammation, and systemic lupus erythematosus.

35 both safe and effective for the treatment of systemic lupus erythematosus.

36 eimer's disease, spinocerebellar ataxia, and systemic lupus erythematosus.

37 AP4K3/GLK(high)IL-17A(high) subpopulation of systemic lupus erythematosus.

38 ted clinical efficacy in off-label trials of Systemic Lupus Erythematosus.

39 as rheumatoid arthritis (98.1%), followed by systemic lupus erythematosus (0.79%), psoriasis (0.79%),

40 is (23 [26.7%]), psoriasis (18 [20.9%]), and systemic lupus erythematosus (12 [14.0%]) were the most

41 ion for the involvement of these proteins in systemic lupus erythematosus(12-14).

42 sis, 6 had inflammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis,

43 ed by CXorf21-a gene that is associated with systemic lupus erythematosus(4,5)-interacts with the end

44 ti-DNA antibodies that are characteristic of systemic lupus erythematosus, a chronic autoimmune disea

45 s are elevated in T cells from patients with systemic lupus erythematosus, a disease characterized by

46 l choline and total creatine, correlate with systemic lupus erythematosus activity.

47 s, rheumatoid arthritis, sicca syndrome, and systemic lupus erythematosus (adjusted OR 1.49 [1.34-1.6

48 tte smoking (aHR, 1.9; 95% CI, 1.1-3.4), and systemic lupus erythematosus (aHR, 3.5, 95% CI, 1.1-11).

49 nulomatosis with Polyangiitis (aHR=0.21), or Systemic Lupus Erythematosus (aHR=0.32).

50 are linked with autoimmune diseases such as systemic lupus erythematosus, Aicardi-Goutieres syndrome

51 more, we examined B cells from patients with systemic lupus erythematosus, an autoimmune disorder wit

52 Hydroxychloroquine used for treating systemic lupus erythematosus and a Syk inhibitor blocked

53 eases that can affect the kidneys, including systemic lupus erythematosus and anti-neutrophil cytopla

54 yA 25-year-old woman with recently diagnosed systemic lupus erythematosus and class IV lupus nephriti

55 An increase in clonality in systemic lupus erythematosus and Crohn's disease that wa

56 story was remarkable for an aunt who died of systemic lupus erythematosus and for a brother with arth

57 ith chronic inflammatory diseases, including systemic lupus erythematosus and inflammatory bowel dise

58 observed within the kidneys of patients with systemic lupus erythematosus and lupus nephritis (LN).

59 d thus represent new therapeutic targets for systemic lupus erythematosus and other diseases involvin

60 pregnancy based on studies in patients with systemic lupus erythematosus and other rheumatic conditi

61 ients with rheumatologic conditions, such as systemic lupus erythematosus and rheumatoid arthritis

62 and co-inhibitory pathways in two systemic (systemic lupus erythematosus and rheumatoid arthritis) a

63 pathology of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis.

64 ted with anti-SSA/Ro autoantibodies, such as systemic lupus erythematosus and Sjogren syndrome, are l

65 ting to the polygenic autoimmune diseases of systemic lupus erythematosus and systemic sclerosis.

66 ls and IgE play a role in the development of systemic lupus erythematosus and thus represent new ther

67 nd are reduced in expression in B cells from systemic lupus erythematosus and type 1 diabetes patient

68 tion in iMCD compared with Hodgkin lymphoma, systemic lupus erythematosus, and reactive lymph nodes,

69 e, such as atherosclerosis, type-2 diabetes, systemic lupus erythematosus, and rheumatoid arthritis.

70 ed aplastic anemia (AA), autoimmune uveitis, systemic lupus erythematosus, and sickle cell disease, r

71 is a disfiguring and common manifestation in systemic lupus erythematosus, and the etiology of this p

72 several inflammatory skin diseases including systemic lupus erythematosus, angioedema, pemphigus, bul

73 Here, we compared the BCR repertoire in systemic lupus erythematosus, anti-neutrophil cytoplasmi

74 he immunopathology observed in patients with systemic lupus erythematosus, autoreactive Abs secreted

75 cells are implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoan

76 a controversial role in the pathogenesis of systemic lupus erythematosus, but the underlying mechani

77 B cells play an important role in systemic lupus erythematosus by acting not only as precu

78 contributions to autoimmune diseases such as systemic lupus erythematosus can differ.

79 cluding Aicardi-Goutieres syndrome (AGS) and systemic lupus erythematosus, can arise when TREX1 funct

80 Systemic lupus erythematosus carries an increased risk o

81 Immune complex-mediated diseases, such as systemic lupus erythematosus, commonly affect the kidney

82 line diffusion values from all patients with systemic lupus erythematosus correlated positively with

83 In systemic lupus erythematosus, defective clearance of apo

84 In systemic lupus erythematosus, deposits of IgG-immune com

85 also in a diverse array of diseases such as systemic lupus erythematosus, diabetes, and cancer.

86 correlation of these diffusivities with the systemic lupus erythematosus disease activity index are

87 pus erythematosus correlated positively with systemic lupus erythematosus disease activity index scor

88 LR9 have opposing effects in mouse models of systemic lupus erythematosus-disease is exacerbated in T

89 Patients with systemic lupus erythematosus exhibit accelerated atheros

90 d that BND cells obtained from patients with systemic lupus erythematosus exhibited increased CD45 ac

91 development of autoreactive B cells in SLE (systemic lupus erythematosus) focus on extrinsic stimuli

92 e with moderate inflammation and humans with systemic lupus erythematosus had similar effects.

93 A focused profiling of systemic lupus erythematosus HiChIP genes identified enh

94 e to complex diseases like Crohn disease and systemic lupus erythematosus, highlighting the value of

95 The expansion was frequent in patients with systemic lupus erythematosus, in which it correlated to

96 n severity of human rheumatoid arthritis and systemic lupus erythematosus, indicating that increased

97 ions such as rheumatoid arthritis, diabetes, systemic lupus erythematosus, inflammatory bowel disease

98 Systemic lupus erythematosus is an autoimmune disease ch

99 Systemic lupus erythematosus is an autoimmune disease th

100 Systemic lupus erythematosus is an inflammatory autoimmu

101 Systemic lupus erythematosus (lupus) is characterized by

102 Systemic lupus erythematosus (lupus) is characterized by

103 llagen vascular/autoimmune disorders such as systemic lupus erythematosus; lymphoproliferative disord

104 27,739), rheumatoid arthritis (n = 25,324), systemic lupus erythematosus (n = 3,951), and/or vasculi

105 show some correlation with neuropsychiatric systemic lupus erythematosus (NPSLE) symptoms.

106 roposed causative agents in neuropsychiatric systemic lupus erythematosus (NPSLE).

107 atologists who care for patients with severe systemic lupus erythematosus or catastrophic antiphospho

108 ype I IFN-driven autoimmune diseases such as systemic lupus erythematosus or psoriasis, but pDCs are

109 R-induced IFN-alpha production in pDC and in systemic lupus erythematosus pathogenesis.

110 ting follicular helper T cells implicated in systemic lupus erythematosus pathogenesis.

111 tis (LN) affects up to 80% of juvenile-onset systemic lupus erythematosus patients (JSLE).

112 These inflammatory DC3s were expanded in systemic lupus erythematosus patients and correlated wit

113 ased monocytic Siglec-1 expression in active systemic lupus erythematosus patients and, additionally,

114 regulations that emerge from the B cells of systemic lupus erythematosus patients can be restored by

115 Because systemic lupus erythematosus patients were shown to acqu

116 About a third of systemic lupus erythematosus patients, however, lack the

117 cells from human healthy controls and human systemic lupus erythematosus patients, metformin inhibit

118 s, eight myasthenia gravis patients, and six systemic lupus erythematosus patients, obtained by next-

119 utoantibody responses and immunopathology in systemic lupus erythematosus patients.

120 P-1-PTEN-SHP-1 axis function in B cells from systemic lupus erythematosus patients.

121 d primary analysis of disease activity among systemic lupus erythematosus patients.

122 in preclinical autoimmunity and established systemic lupus erythematosus, plasmacytoid dendritic cel

123 ection, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus predispose to atherosclerot

124 ion with more advanced disease did not alter systemic lupus erythematosus progression.

125 re associated with type I diabetes mellitus, systemic lupus erythematosus, RA, and celiac disease, th

126 netic causes of an autoimmune disease called systemic lupus erythematosus reveals a new twist on an o

127 is (rg = 0.18 +/- 0.07, P = 7.78 x 10-3) and systemic lupus erythematosus (rg = 0.13 +/- 0.05, P = 3.

128 meostasis and autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis and s

129 a) diseases, and autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis).

130 uss the current and future impact of AMDs on systemic lupus erythematosus, rheumatoid arthritis, and

131 emic autoimmune connective tissue disorders: systemic lupus erythematosus, rheumatoid arthritis, syst

132 Systemic lupus erythematosus severity correlates with el

133 Basophils from patients with systemic lupus erythematosus show an activated phenotype

134 e diseases, such as rheumatoid arthritis and systemic lupus erythematosus, show a polygenic inheritan

135 spectrum disorder; systemic diseases such as systemic lupus erythematosus, Sjogren syndrome or Behcet

136 e 1 diabetes (T1D) (n = 200, HD n = 200), 3) systemic lupus erythematosus (SLE) (n = 200, HD n = 67;

137 Type I interferon (IFN) drives pathology in systemic lupus erythematosus (SLE) and can be tracked vi

138 i-C1q) are frequently found in patients with systemic lupus erythematosus (SLE) and correlate with th

139 Human C1q deficiency is associated with systemic lupus erythematosus (SLE) and increased suscept

140 Patients with systemic lupus erythematosus (SLE) and primary Sjogren's

141 is of autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthri

142 For instance, the autoimmune diseases systemic lupus erythematosus (SLE) and Sjogren's syndrom

143 autoantigen in autoimmune disorders such as systemic lupus erythematosus (SLE) and Sjogren's syndrom

144 toid arthritis (RA), osteoarthritis (OA), or systemic lupus erythematosus (SLE) and to identify metab

145 Patients with systemic lupus erythematosus (SLE) are at increased risk

146 asma cells in lupus models and patients with systemic lupus erythematosus (SLE) arise as a consequenc

147 um IL-23 and IL-23 receptor in patients with systemic lupus erythematosus (SLE) as compared with heal

148 Circulating Tfh cells from patients with systemic lupus erythematosus (SLE) but not primary antip

149 onsidered to be the major IFNalpha source in systemic lupus erythematosus (SLE) but their phenotype a

150 Systemic lupus erythematosus (SLE) can directly affect v

151 Although pregnancy in systemic lupus erythematosus (SLE) carries a high risk f

152 tegration of gene expression data to predict systemic lupus erythematosus (SLE) disease activity is a

153 Patients with systemic lupus erythematosus (SLE) display a complex blo

154 T cells from patients with systemic lupus erythematosus (SLE) display a number of a

155 Patients with Systemic lupus erythematosus (SLE) experience various pe

156 Systemic lupus erythematosus (SLE) flares elicit progres

157 Patients with systemic lupus erythematosus (SLE) frequently show sympt

158 Systemic lupus erythematosus (SLE) has a strong but inco

159 ouble-blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a profound

160 Patients with systemic lupus erythematosus (SLE) have accelerated card

161 Numerous risk alleles for systemic lupus erythematosus (SLE) have now been identif

162 gh their effects on autoimmune diseases like systemic lupus erythematosus (SLE) have yet to be invest

163 Systemic lupus erythematosus (SLE) impacts multiple orga

164 as diabetes, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) increase susceptibili

165 Systemic lupus erythematosus (SLE) is a chronic, life-th

166 Systemic lupus erythematosus (SLE) is a clinically heter

167 Systemic lupus erythematosus (SLE) is a complex autoimmu

168 Systemic lupus erythematosus (SLE) is a complex autoimmu

169 Systemic lupus erythematosus (SLE) is a devastating auto

170 Systemic lupus erythematosus (SLE) is a heterogeneous au

171 Systemic lupus erythematosus (SLE) is a heterogeneous di

172 Systemic lupus erythematosus (SLE) is a known risk facto

173 Systemic lupus erythematosus (SLE) is a multi-organ auto

174 Systemic lupus erythematosus (SLE) is a multi-organ auto

175 Systemic lupus erythematosus (SLE) is a multisystem, chr

176 Systemic lupus erythematosus (SLE) is a prototypic autoi

177 Systemic lupus erythematosus (SLE) is a prototypic autoi

178 Systemic lupus erythematosus (SLE) is a systemic autoimm

179 Systemic lupus erythematosus (SLE) is an autoimmune dise

180 Systemic lupus erythematosus (SLE) is an autoimmune dise

181 Systemic lupus erythematosus (SLE) is an autoimmune dise

182 Systemic lupus erythematosus (SLE) is an autoimmune dise

183 Systemic lupus erythematosus (SLE) is an autoimmune dise

184 Systemic lupus erythematosus (SLE) is an autoimmune dise

185 Systemic lupus erythematosus (SLE) is an autoimmune diso

186 Systemic lupus erythematosus (SLE) is an autoimmune infl

187 Systemic lupus erythematosus (SLE) is an incurable autoi

188 Systemic lupus erythematosus (SLE) is associated with an

189 Systemic lupus erythematosus (SLE) is characterized by a

190 Systemic lupus erythematosus (SLE) is characterized by b

191 Systemic lupus erythematosus (SLE) is characterized by t

192 Systemic lupus erythematosus (SLE) is defined by loss of

193 Systemic lupus erythematosus (SLE) is mediated by a chro

194 Systemic lupus erythematosus (SLE) is mediated by autore

195 Systemic Lupus Erythematosus (SLE) is the prototype of a

196 Systemic lupus erythematosus (SLE) is the prototypic sys

197 teraction is involved in the pathogenesis of systemic lupus erythematosus (SLE) is unclear.

198 e population-based studies have been done on systemic lupus erythematosus (SLE) mortality trends in t

199 erance, CD33/LAIR-1 expression is reduced in systemic lupus erythematosus (SLE) myelomonocytes.

200 a with greater coagulant effects compared to systemic lupus erythematosus (SLE) non APS IgG.

201 is and an autoimmune response reminiscent of systemic lupus erythematosus (SLE) occurs in its absence

202 Despite advances in understanding systemic lupus erythematosus (SLE) pathogenesis, most cl

203 FN (IFN-I), cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis.

204 characterize total serum antibody Fabs in a systemic lupus erythematosus (SLE) patient sample and co

205 on chr10p12.31 was replicated in a cohort of systemic lupus erythematosus (SLE) patients (N = 47) and

206 Most systemic lupus erythematosus (SLE) patients are photosen

207 disease-implicated lymphocytes isolated from systemic lupus erythematosus (SLE) patients compared to

208 CD4(+) T-cells in systemic lupus erythematosus (SLE) patients show altered

209 ccessibility landscape of naive B cells from Systemic Lupus Erythematosus (SLE) patients undergoing d

210 Circulating levels of leptin are elevated in systemic lupus erythematosus (SLE) patients, but it is n

211 The etiology of the autoimmune disorder systemic lupus erythematosus (SLE) remains poorly unders

212 thin 1 year of thrombosis), and only 6.8% of systemic lupus erythematosus (SLE) sera.

213 l loci have been found to be associated with systemic lupus erythematosus (SLE) susceptibility by a r

214 ional outcome of 39 variants associated with Systemic Lupus Erythematosus (SLE) through the integrati

215 Arthritis is a common manifestation of systemic lupus erythematosus (SLE) yet understanding of

216 dentification in autoimmune diseases such as systemic lupus erythematosus (SLE)(1).

217 ack women are disproportionately affected by systemic lupus erythematosus (SLE), a chronic, potential

218 r, their role in autoimmune diseases such as systemic lupus erythematosus (SLE), a condition characte

219 ns within IRF5 are associated with a risk of systemic lupus erythematosus (SLE), and mice lacking Irf

220 nodeficiency (CVID), Evans syndrome (ES), or systemic lupus erythematosus (SLE), and most achieved a

221 pathogenesis in autoimmune diseases, such as systemic lupus erythematosus (SLE), but the natural hist

222 unction in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying m

223 TLR7 is associated with development of systemic lupus erythematosus (SLE), but the underlying m

224 lay a critical role in autoimmunity, such as systemic lupus erythematosus (SLE), by helping B cells.

225 e pathogenesis of autoimmunity, most notably systemic lupus erythematosus (SLE), diabetes mellitus, a

226 ssociated with smoking, hyperopia, diabetes, systemic lupus erythematosus (SLE), greater deprivation

227 Here we found that in human systemic lupus erythematosus (SLE), IgE antibodies speci

228 esses that contribute to the pathogenesis of systemic lupus erythematosus (SLE), including autoreacti

229 on feature of autoimmune diseases, including systemic lupus erythematosus (SLE), is an increased prev

230 In systemic lupus erythematosus (SLE), LL37 also triggers I

231 The heterogeneity of systemic lupus erythematosus (SLE), long recognised by c

232 In systemic lupus erythematosus (SLE), many self-antigens a

233 with several autoimmune diseases, including systemic lupus erythematosus (SLE), Sjogren's syndrome,

234 In systemic lupus erythematosus (SLE), these antibodies bin

235 In systemic lupus erythematosus (SLE), this cross-talk was

236 redicting the susceptibility and severity of systemic lupus erythematosus (SLE), using renal disease

237 receptor 7 (TLR7)-dependent mouse models of systemic lupus erythematosus (SLE), we dissect dietary e

238 s also linked to autoimmune diseases such as systemic lupus erythematosus (SLE), where nucleic acid-c

239 DLDs) and choroidal changes in patients with systemic lupus erythematosus (SLE), with or without glom

240 hway to autoimmune diseases, with a focus on systemic lupus erythematosus (SLE), with the relevant tr

241 DNA (dsDNA) are prevalent and pathogenic in systemic lupus erythematosus (SLE), yet mechanisms of th

242 Cutaneous inflammation is recurrent in systemic lupus erythematosus (SLE), yet mechanisms that

243 ferative glomerulonephritis, which resembled systemic lupus erythematosus (SLE)-like autoimmune disea

244 yeloid cells (LysM(Cre)Bim(fl/fl)) develop a systemic lupus erythematosus (SLE)-like disease that mir

245 ription factor T-bet promote autoimmunity in Systemic Lupus Erythematosus (SLE)-prone mouse models, t

246 seases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

247 utoimmunity is central to the development of systemic lupus erythematosus (SLE).

248 ells are correlated with disease severity of systemic lupus erythematosus (SLE).

249 9) is a regulator of disease pathogenesis in systemic lupus erythematosus (SLE).

250 e to tissue inflammation and organ damage in systemic lupus erythematosus (SLE).

251 d patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).

252 ding CD11b) strongly associate with risk for systemic lupus erythematosus (SLE).

253 associated with autoimmune diseases, such as systemic lupus erythematosus (SLE).

254 inal centers in spontaneous murine models of systemic lupus erythematosus (SLE).

255 utoantibodies for diagnosis and prognosis of Systemic Lupus Erythematosus (SLE).

256 ontrols and 11 patients with well-controlled systemic lupus erythematosus (SLE).

257 r lupus nephritis, a serious complication of systemic lupus erythematosus (SLE).

258 et the nucleoli, are pathogenic hallmarks of systemic lupus erythematosus (SLE).

259 FSF13B locus-specific association testing in systemic lupus erythematosus (SLE).

260 ion factor implicated in the pathogenesis of systemic lupus erythematosus (SLE).

261 ents of the comprehensive care of women with systemic lupus erythematosus (SLE).

262 s to DNA and chromatin drive autoimmunity in systemic lupus erythematosus (SLE).

263 organ damage in autoimmune diseases such as systemic lupus erythematosus (SLE).

264 een proposed to underlie the pathogenesis of systemic lupus erythematosus (SLE).

265 D11b, confer risk for the autoimmune disease systemic lupus erythematosus (SLE).

266 ected against nuclear Ags is the hallmark of systemic lupus erythematosus (SLE).

267 (HCMV) has been linked to the triggering of systemic lupus erythematosus (SLE).

268 pe I interferon (IFN) are hallmarks of human systemic lupus erythematosus (SLE).

269 of the variations causing susceptibility to systemic lupus erythematosus (SLE).

270 ss-switched autoantibodies are a hallmark of systemic lupus erythematosus (SLE).

271 gan manifestations of the autoimmune disease systemic lupus erythematosus (SLE).

272 temic autoimmunity and organ inflammation in systemic lupus erythematosus (SLE).

273 ell responses and plays a pathogenic role in systemic lupus erythematosus (SLE).

274 ck CD4 and CD8 coreceptors and contribute to systemic lupus erythematosus (SLE).

275 n several autoimmune diseases, in particular systemic lupus erythematosus (SLE).

276 s (BCR), promote an autoinflammatory loop in systemic lupus erythematosus (SLE).

277 ulation is implicated in the pathogenesis of systemic lupus erythematosus (SLE).

278 stant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

279 erived from patients with autoimmune disease systemic lupus erythematosus (SLE).

280 ic variants are associated with the risk for systemic lupus erythematosus (SLE); however, it is uncle

281 plicated in the inflammation associated with systemic lupus erythematosus (SLE); however, it remains

282 fluid (CSF) and plasma from 35 patients with systemic lupus erythematosus (SLE; 15 with NPSLE) showed

283 Systemic lupus erythematosus (SLE; OMIM 152700) is a gen

284 ated in patients with systemic sclerosis and systemic lupus erythematosus, suggesting a way to charac

285 th other connective tissue diseases, such as systemic lupus erythematosus, systemic sclerosis, and my

286 atic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, vascul

287 nephritis (LN) is a common manifestation of systemic lupus erythematosus that can lead to irreversib

288 ting polyneuropathy, Sjogren's syndrome, and systemic lupus erythematosus that have been controlled w

289 Systemic lupus erythematosus was excluded from all patie

290 Using an inducible model of systemic lupus erythematosus, we found that passive tran

291 from patients with rheumatoid arthritis and systemic lupus erythematosus were demethylated compared

292 7-mediated model of autoimmunity, similar to systemic lupus erythematosus, where both cell types are

293 al alterations in the brain of patients with systemic lupus erythematosus with and without a history

294 NASE1L3 deficiency causes familial monogenic systemic lupus erythematosus with childhood onset and an

295 y of the corpus callosum of 13 patients with systemic lupus erythematosus with past NPSLE, 16 patient

296 In patients with systemic lupus erythematosus with past NPSLE, significan

297 lated with disease activity in patients with systemic lupus erythematosus with plasmablast-associated

298 comparisons were made between patients with systemic lupus erythematosus with/without past NPSLE and

299 is one of the most severe manifestations of systemic lupus erythematosus, with considerable morbidit

300 thematosus with past NPSLE, 16 patients with systemic lupus erythematosus without past NPSLE, and 19